MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Akciju saraksts・ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

78.94 -0.18

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

78.36

Max

79.5

Galvenie mērījumi
By Trading Economics
Ienākumi	18M 27M
Pārdošana	16M 228M
P/E Sektora vidējais	51.506 88.032
Peļņas marža	11.684
Darbinieki	897
EBITDA	19M 61M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+38.19% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-269M 1.8B
Iepriekšējā atvēršanas cena	79.12
Iepriekšējā slēgšanas cena	78.94

Ziņu noskaņojums

By Acuity

25%

75%

50 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

70.05 / 71.85 Atbalsts un pretestība

ANI Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. dec. 22:20 UTC

Galvenie tirgus virzītāji

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025. g. 31. dec. 17:31 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025. g. 31. dec. 16:30 UTC

Galvenie tirgus virzītāji

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025. g. 31. dec. 15:19 UTC

Galvenie tirgus virzītāji

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025. g. 31. dec. 15:17 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025. g. 31. dec. 14:37 UTC

Galvenie tirgus virzītāji

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025. g. 31. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:13 UTC

Iegādes, apvienošanās, pārņemšana

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025. g. 31. dec. 20:40 UTC

Tirgus saruna

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025. g. 31. dec. 20:22 UTC

Tirgus saruna

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025. g. 31. dec. 19:50 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025. g. 31. dec. 19:31 UTC

Tirgus saruna

Precious Metals Cap Off Record Runs -- Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025. g. 31. dec. 17:17 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025. g. 31. dec. 17:16 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025. g. 31. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 31. dec. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025. g. 31. dec. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025. g. 31. dec. 15:54 UTC

Tirgus saruna

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025. g. 31. dec. 15:02 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025. g. 31. dec. 14:40 UTC

Iegādes, apvienošanās, pārņemšana

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025. g. 31. dec. 14:20 UTC

Tirgus saruna

Crude Futures On Track to End the Year With Losses -- Market Talk

2025. g. 31. dec. 13:46 UTC

Tirgus saruna

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025. g. 31. dec. 13:01 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025. g. 31. dec. 11:10 UTC

Tirgus saruna

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025. g. 31. dec. 10:46 UTC

Tirgus saruna

Euro on Track For Strong Annual Performance -- Market Talk

2025. g. 31. dec. 10:25 UTC

Tirgus saruna

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025. g. 31. dec. 10:23 UTC

Tirgus saruna

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025. g. 31. dec. 09:33 UTC

Tirgus saruna

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Salīdzinājums

Cenas izmaiņa

ANI Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

38.19% augšup

Prognoze 12 mēnešiem

Vidējais 109.75 USD 38.19%

Augstākais 121 USD

Zemākais 100 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ANI Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ANI Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

70.05 / 71.85Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bullish.

Noskaņojums

By Acuity

50 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.